Navigation Links
Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board

The Madras High Court in the southern Indian state of Tamil Nadu has decided to transfer the Novartis AG’s appeal against the rejection of its patent// plea for the anti-cancer drug Glivec to the Intellectual Property Appellate Board.

The decision could be considered a temporary setback to the pharma multinational.

For it cannot hope for any early decision on the patent plea. The Appellate Board’s ruling too can be challenged it in the courts.

To add to Novartis’ miseries the technical member of the new appellate court will be none other than Chandrasekaran, former Controller General of the Indian Patent Office, who had rejected its application for Glivec patent. A spokesperson of the Novartis has already expressed concern over Chandrasekaran’s appointment.

The Madras High Court has already reserved its orders on the main petition by the Novartis challenging the constitutional validity of the Section 3(d) of the Patents (Amendment) Act.

Novartis contends the amendment contravenes the trade-related intellectual property rights (TRIPS) and also Article 14 of the Indian Constitution, which ensures equality before the law.

The section 3(d) of India’s 2005 Patent Amendment Act interprets the trade-related intellectual property rights (TRIPS) treaty. It prohibits patents for a new form of a known substance unless that new form has considerably better efficacy.

Novartis’s Glivec was a new form of an older molecule that it first patented in 1993. The enhancement in efficacy over the old form was not large enough to warrant a patent, the Patent Controller of India held in January last year.

The company then approached Madras High Court as the Controller’s office is situated in Chennai. It wanted rejection of patent application set aside. That appeal goes before the appellate board set up by the government of India for the purpose.

But orders on the Novartis’ challenge of the amendment to the patents law have been reserved. They could be delivered in a month or so from now.

And if a company like the Novartis gets its step in the door, asserting its right to patent even minor modifications of existing formulations, drug prices could go through the roof.

No firm then can manufacture generic drugs, which are less expensive. As patents near expiration, manufacturers apply for permission to sell generic versions. Because those manufacturers don’t have the same development costs, they can sell their product at substantial discounts. Also, once generic drugs are approved, there is greater competition, which keeps the price down. Today, almost half of all prescriptions are filled with generic drugs. Generic variations are introduced in colors, flavors, and certain other inactive ingredients.

To cite a specific example of the benefits of generic versions, the cost of patented HIV/AIDS drugs is huge whereas the generic is very cheap and affordable. Hence activists the world have raised serious concerns over the Novartis case in the Madras High Court.

The company has patented Glivec in nearly 40 countries worldwide and says it wants to ensure that it will get adequate patent protection for any drugs it plans to offer in India in the future. 'For a research-based organisation like Novartis, patents are non-negotiable, said a spokesperson for Novartis. 'This is the core of our business model and we cannot work in markets where there aren’t effective patent systems. It’s not about stopping generics. We are a major generics manufacturer.'

The stakes are high, say activists. 'Should Novartis succeed in its challenge, it will mark the first time that the demands of a private multinational corporation have overridden a sovereign country’s right to protect the health of its people,' said Chan Park of the Lawyers’ Collective HIV/AIDS Unit in New Delhi, which has campaigned against the case. < br>
Source-Medinia
GPL/B
'"/>




Related medicine news :

1. Indian Prime Minister has successful Knee Replacement Surgery
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Indian Doctor granted US patent on organ regeneration
4. Heart attack kills one in every 10 Indians
5. Indian Cherry: Richest Source of Vitiamin C
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. An Indian Bride with signs of SARS
8. Are Indians aware of SARS ?
9. Indians Stay Away from Coke, Pepsi After Toxin Scare
10. Indian pharma industry upbeat on WTO drug deal
11. Indian Treatment for Iraqi Babies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... 2016 , ... More than 100 business, civic, community and ... the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This inaugural event, hosted by ... support to UNCF-member institutions, including Miles College, Oakwood University, Tuskegee University, Stillman College ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the ... how he was inspired to practice medicine at an early age by his father, ... than making diagnoses and prescribing medicine,” he states. “It is about building relationships with ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to ... which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping ... prolonging life 6 years in the last 3 decades,” says Dr. Valentine Fuster, ...
(Date:12/2/2016)... ... 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique ... other wearable health technology on the market can deliver all that rejiva can. , ... insights about their health than the usual heart rate and steps taken”, adds Evens ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... organizations to build intelligent, connected applications, was named the best Sales Team of ... The winner announcement was made today by the Software & Information Industry Association ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... December 2, 2016 According ... Diagnostics/IVD Market by Product (Instruments, Reagents, Software), Technology ... Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to ... valued at USD 60.22 Billion in 2016. This ... of 5.5% during the forecast period (2016-2021) to ...
(Date:12/2/2016)... 2, 2016  The Addiction Treatment Advisory Group ... Managed Care Pharmacy (AMCP), has released detailed findings ... the opioid addiction crisis, including through improved access ... ATAG,s newly released paper, "The Role of ... addresses many issues around gaps and barriers to ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific ... definitive agreement to acquire certain manufacturing assets and capabilities ... (TSX: NVC) advanced biological tissue business, as well as ... of $75 million in cash. The Neovasc advanced biological ... including the Boston Scientific Lotus™ Valve System. * ...
Breaking Medicine Technology: